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Objectives: Development of an intraluminal device to reduce aortic regur- 
gitation could provide a strategy intermediate between medical treatment 
and aortic valve replacement. An initial prototype and a testing system have 
been designed. Methods: Aortic valves obtained from heart transplant 
recipients were explanted and assessed in a mock circulatory loop with 
resistive and capacitive elements, including pressure-flow characteristics, 
similar to those of a normal arterial system. Normal heart function was 
simulated by a pulsatile ventricular-assist device. Pressure on each side of 
the valve and flow through the valve were recorded, allowing the calculation 
of regurgitant fractions and transvalvular gradients. Six solid geometrically 
differing obturators were tested. Results: All six designs resulted in signif- 
icant reduction in aortic regurgitation (p < 0.0001), ranging from 15% to 
38% improvement compared with control values. Small increases in 
transvalvular gradients (from 0 to 7 mm Hg) were also noted. Discussion: 
Initial results suggest that an intraluminaily placed obturator can reduce 
aortic regurgitation without creating clinically significant transvalvular 
gradients. These initial in vitro experiments demonstrate the feasibility of 
an intraluminal device for the treatment of aortic valve disease, and further 
investigation is warranted. (J Thorac Cardiovasc Surg 1996;112:979-83) 
A ortic valve disease accounts for an estimated 40,000 hospital admissions per year in the 
United States. 1Most of these admissions result in 
aortic valve replacement, with approximately 20% 
of these procedures conducted to treat aortic 
regurgitation (AR). The total number of persons 
with AR who are treated as outpatients and are 
not under medical care is difficult to determine. 
Most of these persons remain free of symptoms 
for years, until left ventricular functions worsens 
and angina, syncope, or congestive heart  failure 
develops. The natural history of AR  is also diffi- 
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cult to determine because many patients with 
asymptomatic AR do not seek medical care until 
symptoms arise. 
Two options currently exist for the treatment of 
AR. Medical management, consisting primarily of 
vasodilator therapy, reduces AR through arteriolar 
vasodilatation. Vasodilators have been shown to 
prevent he deterioration of left ventricular dysfunc- 
tion in symptom-free persons and thus prevent or 
delay the need for an operation to replace the 
diseased aortic valve. Once symptoms or left ven- 
tricular dysfunction has occurred, aortic valve re- 
placement is indicated. 2 
Because of the risks associated with surgical pro- 
cedures and the palliative nature of medical treat- 
ment options, an intermediate and minimally inva- 
sive treatment to correct AR would be beneficial. 
Previous work in this area has focused on the 
development of implantable valves to correct dis- 
eased native valves. 34 The device we have devel- 
oped, known as an aortic valve obturator, would be 
placed intraluminally and secured above th native 
aortic valve to the aortic wall. The obturator is 
intended to enlarge the armamentarium of treat- 
ment options for AR  and could become the long- 
term treatment of choice for selected patients. 
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Fig. 1. Mock circulatory loop system used to test aortic 
valves. This system simulates physiologic pressure-flow 
characteristics of normal human arterial system./, Pulsa- 
tile ventricular-assist device (Abiomed BVS 5000). 2, 
Housing chamber for human aortic valves and obturator. 
3, Flow probe to measure flows through system. 4, Capac- 
itance chamber 1 to aid in regulation of pressure. 5, 
Capacitance chamber 2 to aid in regulation of pressure. 6, 
Resistance lement o create diastolic pressure. 7, Fluid 
reservoir of system. 8, Console of Ventricular-assist device 
to simulate normal heart function. 9, Computer and 
MacLab to record pressures and flows within system. 
Methods 
Aortic valves, At the time of cardiac transplantation, 
aortic valves including the anulus and a portion of the 
ascending aorta were dissected from discarded recipient 
hearts. The valves were then stored in normal saline 
solution with antibiotics and refrigerated until testing. 
Before testing, the valve leaflets were shortened to create 
Significant regurgitation. 
Testing system. To simulate the characteristics of the 
normal arterial system, a mock circulatory !oop system 
was created. This system was based on previous models of 
pulse duplicator systems for the testing of prosthetic 
valves (Fig. 1). To simulate physiologic pressure-flow 
characteristics, resistive and capacitance elements were 
integrally designed components of the system. 
The system was powered by the Abiomed BVS 5000 
ventricular-assist device (Abiomed, Inc, Danvers, Mass.). 
This pulsatile pneumatic pump is driven by an electrome- 
chanical console and contains two polyurethane chambers 
in a polycarbonate housing. A three-leaflet polyurethane 
valve separates the gravity-filled atrial chamber from the 
air-actuated ventricular chamber. A second valve, located 
on the outlet ventricular chamber, was secured in the 
open position for the pUrposes of our experiment. The 
Abiomed console was driven by a foot pump for better 
regulation of the pulse rate and pressure in our system. 
The housing chamber for the experimental human 
aortic valves is shown in Fig. 2. This chamber, along with 
the two capacitance chambers, were made of acrylic 
Fig. 2. Housing chamber for aortic valves. This chamber 
is composed of acrylic and consists of inflow and outflow 
conduits through which transducers measure pressure on 
each side of aortic valve. Obturator is introduced through 
top of this chamber, and valves are situated in sleeves 
within chamber. 
polymer. The housing chamber consisted of inflow and 
outflow conduits through which pressure transducer cath- 
eters were situated. Aortic valves Contained within de- 
signed sleeves were placed in the center of this chamber. 
The sleeves allowed the valve anulus to undergo dynamic 
changes, simulating i  vivo conditions. The obturators, 
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Table I. Regw~itant fractions of aortic valves before 
(conuvl) and after obturator placement 
Design* Contlvl (%) Obturator (%) % Reduction p 
1 29 --+ 8 22 _+ 8 24 0.0001 
2 30 --+ 11 22 _+ 7 27 0.0001 
3 26 _+ 8 22 --+ 8 15 0.0015 
4 27 _+ 7 20 + 6 26 0.0001 
5 29 _+ 7 18 -+ 6 38 0.0001 
6 28 _+ 9 18 --+ 6 36 0.0001 
Values are -+ standard eviation. 
*Design numbers correspond to Fig. 3. 
designed to reduce AR, were introduced through the top 
of this chamber. These obturators could be positioned 
within or above the valve and were could be completely 
removed from the flow canal. 
The capacitance system consisted of two chambers. The 
first chamber was air-filled, which allowed fluid from the 
circuit to be maintained at a designated level during 
system operation. The second chamber housed a l~-inch 
diameter Penrose drain, through which fluid from the 
system flowed. This was surrounded by an air-sealed 
compartment that was pressure regulated to adjust the 
elasticity of the system. A clamp was placed distal to the 
chambers to create resistance in the system, which directly 
correlated with the diastolic pressure component of our 
system. These elements were manipulated to simulate the 
characteristics of in vivo arterial circulation. The entire 
circuit was connected with 70 Durameter 1/2-inch tubing 
(Baxter Healthcare Corp., Bentley Div., Irvine, Calif.). 
Normal saline solution at room temperature was the 
principal fluid used in this investigation. 
Pressure measurements on each side of the valve were 
recorded with pressure transducers (Millar Instruments, 
Inc., Houston, Texas). The pressure transducers were 
placed 2 cm from each side of the valve. A tubing flow 
probe (Transonic Systems Inc., Ithaca, N.Y.) was used to 
measure the foiward and reverse flows through the valves. 
Data were digitized in real time at speed of 200 Hz with an 
analog-digital converter (MacLab/8, model MacLab 
MkIII; Ad Instruments Pty Ltd., Castle Hill, Australia) 
and recorded with a Macintosh computer (Power Macin- 
tosh 7100/80; Apple Computer, Inc., Cupertino, Calif.). 
Computer processing of the digitized data (Igor; Wavem- 
etrics, Inc., Lake Oswego, Ore.) allowed determination of
the pressure gradients across the valve and of regurgitant 
fraction through the valve. Regurgitant fraction was cal- 
culated by dividing the integral of the regurgitant flow 
curve by the integral of the curve for antegrade flow. 
Obturator design. Six solid plastic obturators were 
designed. Fig. 3 illustrates the shapes, with a description 
of each obturator. 
Experimental procedure. The aortic valves were first 
sewn into the sleeves and then placed within the testing 
chamber. The system was primed, and the manually 
powered pump was started. The pulse rate was kept at 
approximately 80 beats/rain, and the pressures were ad- 
justed to between 120 and 160 mm Hg systolic and 
between 70 and 90 mm Hg diastolic. Flow through the 
valve was approximately 3 L/rain. 
1o 
Fig. 3. Aortic valve obturators. 1, Solid ball. 2, Solid 
diamond. 3, Solid pyramid with straight sides. 4. Solid 
pyramid with concave sides. 5, Hollow pyramid with 
straight sides. 6, Hollow pyramid with concave sides. 
Recordings were obtained at baseline (control). The 
obturator was then positioned at the level of the valve and 
recordings were repeated. This procedure was repeated 
four times, so that four paired sets of data were obtained 
for each obturator with each valve tested. The study 
period for each valve was approximately 2 hours. During 
this time there was no significant deterioration i  valve 
function, as ensured by using each valve as its own control 
before placement of the obturator. The regurgitant frac- 
tions for each valve remained constant hroughout the 
study period. Analysis of each separate recording was 
conducted, with gradients and regurgitant fractions tabu- 
lated along with statistical analysis performed. 
Statistical analysis. Data were analyzed with SAS soft- 
ware (Statistical Analysis System, Cary, N.C.) on the 
Columbia Presbyterian Department of Surgery computer 
system. A mixed model (random and fixed factors), two- 
way analysis of variance was used for the analysis of 
balanced, replicate-measure data. Device treatment was 
considered a fixed effect, and the four valves used were 
considered random effects. Ap  value lower than 0.05 was 
considered significant. 
Results 
Four separate valves were tested with six different 
obturators. All obturators resulted in significant 
reductions in regurgitant fractions. Devices 5 and 6 
(Fig. 3) resulted in the most significant reductions in 
AR,  38% and 36%, respectively. Obturator 3 re- 
duced regurgitation by only 15%, which was still a 
statistically significant reduction (p < 0.0001). 
No device created clinically significant aortic gra- 
dients. Device 3 resulted in the largest average 
gradient (7 + 9 mm Hg). A summary of  regurgitant 
fractions and gradients is shown in Tables I and II. 
Table I I I  details both the antegrade and regurgitant 
flows through the valves for each device. 
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Table II. Transvalvular g adients before (control) 
and after obturator placement 
Design* Control (rnm Hg) Obturator ( nm Hg) p 
1 0 ± 3 4 + 6 0.001 
2 0 ± 2 0 ± 3 0.001 
3 0 -+ 7 7 ± 9 0.001 
4 0 ± 4 5 ± 7 0.001 
5 0 ± 4 5 ± 7 0.001 
6 0 + 4 6 + 7 0.001 
Values are -+ standard eviation. 
*Design numbers correspond to Fig. 3. 
Discussion 
Age, degree of left ventricular dysfunction, and 
symptoms guide physicians in determining the opti- 
mal treatment for patients with AR. When opera- 
tion is delayed until left ventricular dysfunction 
occurs, outcomes vary; depressed preoperative ejec- 
tion fraction and elevated left ventricular end-dia- 
stolic pressure are predictors of mortality. 6-8 Alter- 
natively, aortic valve replacement in symptom-free 
patients with normal left ventricular function ex- 
poses them to the risks related to operation, antico- 
agulation, and prosthetic valves. 
The natural history of chronic AR is excellent in 
symptom-free patients with normal left ventricular 
function who are treated with conservative, nonop- 
erative management. Bonow and colleagues 9 fol- 
lowed up 77 patients for 7 years and found that 75% 
remained free of symptoms and had normal left 
ventricular function. Surveillance guidelines for 
these patients are therefore extremely important. 
Although the development of symptoms is readily 
apparent, deteriorating left ventricular function is 
not. Compensation of the left ventricle by hypertro- 
phy and dilation requires close observation because 
survival is directly correlated with left ventricular 
function. 6q° 
Optimal management for individual patients is 
variable, with vasodilator therapy and operation the 
opposite nds of the spectrum. Hydralazine, nifedi- 
pine, and enalapril have all shown beneficial effects 
in the treatment of patients with AR who are free of 
symptoms and have normal left ventricular func- 
tion. 11-~3 Medical management is effective in pro- 
longing the time to aortic valve replacement, al- 
though ventricular function continues to deteriorate 
at a slow rate. 
At the other end of the spectrum is an operation 
to replace the diseased aortic valve. Mortality rates 
as low as 1.5% have been reported for elective, 
isolated aortic valve operations, s Mortality rates 
Table III. Antegrade and regurgitant flows of valves 
tested before (control) and after obturator placement 
Control Obturator 
Antegrade Regurgitant Antegrade Regurgitant 
Design * (L/min) (L/min) (L/min) (L/min) 
1 2,93 -+ 0.25 0.84 + 0.09 2.90 -+ 0.32 0.67 ± 0.08 
2 2,93 +- 0.15 0.88 + 0.07 2.92 +- 0.22 0.64 ± 0.05 
3 3.10 ± 0.21 0.80 ± 0.06 2.91 _+ 0.21 0.64 + 0.07 
4 3.00 + 0.10 0.81 ± 0.06 2.83 ± 0.37 0.56 + 0.06 
5 2.98 ± 0.25 0.86 + 0.09 2.85 -+ 0.45 0.51 + 0.09 
6 3.07 + 0.21 0.86 ± 0.09 2.84 ± 0.42 0.51 + 0.09 
Values are ± standard eviation. 
*Design numbers correspond to Fig. 3. 
increase significantly with additional risk factors 
such as urgency, age, left ventricular end-diastolic 
pressure, ejection fraction, cardiac index, functional 
class, bypass time, and extent of coronary dis- 
ease.6, a, 14-16 AR has itself been demonstrated to be 
an independent risk factors for operative mortali- 
ty. 14 Along with the surgical risk factors, the pros- 
thetic valve poses risks of stroke, infection, and 
anticoagulation. In addition, aortic valve reopera- 
tion increases the risk of mortality. 
The concept of treating AR without replacement 
of the native aortic valve originated with a valve 
prosthesis implanted in the descending aorta. 17 
Since that time, surgical correction of valvular dis- 
ease has focused on replacement of the diseased 
valve with either mechanical or biologic valves in the 
anatomic position. Alternative treatment of AR has 
focused mainly on transluminal valves positioned 
above the native valve. 3-s' 18, 19 
A less invasive treatment than aortic valve re- 
placement would allow physicians to be more ag- 
gressive in addressing regurgitant aortic valves. Two 
experimental approaches currently being investi- 
gated are transluminal valve replacement and an 
external root device to decrease annular dila- 
tion.5, 18-20 Both are still in the early animal testing 
phases, with no reported patient rials. 
Percutaneous placement of an obturator through 
the femoral artery is one alternative that could 
potentially decrease AR substantially through a 
solely transluminal approach. Several groups of 
patients would appear to benefit immediately from 
this type of device. Potential candidates are patients 
with acute regurgitation, inwhom risks of operation 
may exceed 40%, elderly persons with poor ejection 
fractions, and other high risk groups in whom the 
risk of operation may outweigh the benefits. De- 
pending on device efficacy, even patients at lower 
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risk could be offered this therapy in lieu of aortic 
valve replacement. 
Development of such an obturator is dependent on 
a testing system that simulates normal physiologic 
conditions to evaluate different obturator designs. The 
mock circulation system the we created allows varia- 
tion of pressures and flows through human aortic 
valves, thus testing obturator designs under different 
conditions. In vitro evaluation of obturators allows 
efficient and expedient testing Of the most appropriate 
design before in vivo implantation. 
The ideal device must satisfy several criteria. 
First, AR must be reduced without creation of an 
aortic gradient. Substituting AR for aortic stenosis 
may be more detrimental to the ventricle than the 
original disease. On the other hand, AR need not be 
eliminated completely, because trivial AR is well 
tolerated. Second, the obturator must be situated 
above the valve without affecting the native valve 
leaflets. Damage to the leaflets would worsen the 
AR, negating any correction by the obturator. Third, 
minimally thrombogenic materials and design would 
greatly enhance the appeal of this device by avoiding 
anticoagulation. Fourth, implantation through a 
transluminal approach would facilitate patient re- 
covery and shorten hospital stay. The technology for 
transluminal placement is becoming refined in the 
areas of endovascular grafts and stents. Similar 
delivery mechanisms will need to be adapted for our 
device in future in vivo experiments. 
Results to date have demonstrated the applicability 
of this device. Inverted, hollow, pyramidal obturators 
appear to be ideally shaped. These obturators signifi- 
cantly reduced AR in vitro without creating stenosis. 
Further experiments evaluating flow dynamics must be 
conducted to increase understanding of the mecha- 
nisms by which our device reduces AR in the ongoing 
attempt o design the ideal obturator. 
Although costly, current medical and surgical 
treatments of AR are both beneficial and effective 
for a broad spectrum of patients. Nevertheless, the 
development of a transluminal obturator would 
supplement current options. Initial experiments 
with prototype obturators has shown this concept o 
be feasible and worthy of further investigation. 
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